NASDAQ:PCSA
Processa Pharmaceuticals Inc. Stock News
$1.81
-0.120 (-6.22%)
At Close: Jul 03, 2024
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (P
Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
08:00am, Monday, 06'th May 2024
HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
08:00am, Tuesday, 30'th Apr 2024
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clini
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
08:15am, Thursday, 28'th Mar 2024
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the n
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
08:15am, Monday, 25'th Mar 2024
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the n
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
08:15am, Wednesday, 21'st Feb 2024
HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
01:00pm, Wednesday, 14'th Feb 2024
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
08:30am, Tuesday, 06'th Feb 2024
HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
04:22pm, Thursday, 01'st Feb 2024
HANOVER, MD, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
09:04am, Friday, 26'th Jan 2024
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the n
Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?
02:40pm, Thursday, 25'th Jan 2024
Clinical-stage pharmaceutical company Processa Therapeutics (NASDAQ: PCSA ) — which specializes in the field of oncology — is skyrocketing on Thursday. PCSA stock is up about 90% as of this writin
What made Processa Pharmaceuticals stock nearly triple on Thursday?
11:29am, Thursday, 25'th Jan 2024
Processa Pharmaceuticals Inc (NASDAQ: PCSA) says it has completed a safety evaluation of its cancer treatment. Its shares rallied well over 150% on Thursday.
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
07:45am, Friday, 19'th Jan 2024
FDA and Processa agree to expand NGC-Cap development into breast cancer providing a more efficient path to approval FDA agrees that existing data and studies can be used to support the Phase 2 breast
Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split
07:45am, Thursday, 18'th Jan 2024
HANOVER, MD, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the ne